title: Tissue miR-193b as a Novel Biomarker for Patients with Ovarian Cancer.
abstract: BACKGROUND MiRNAs play important roles in regulating many fundamental biological processes. Deregulation of miRNAs is involved in the initiation and progression of cancer. MiR-193b is regarded as tumor suppressor in many types of cancers. However, the role of miR-193b in ovarian cancer is poorly understood. MATERIAL AND METHODS The expression level of miR-193b in ovarian cancer cell lines and ovarian cancer samples was evaluated using quantitative real-time reverse transcription-PCR (qRT-PCR). The ovarian cancer patients were categorized into a high miR-193b expression group and a low miR-193b expression group according to the median miR-193b expression level. The correlation between tissue miR-193b expression and the patients' clinicopathological factors, as well as survival, was also analyzed. RESULTS The results showed that the miR-193b expression was significantly down-regulated in ovarian cancer cell lines and tumor tissues compared with normal controls. In addition, tissue miR-193b expression was positively correlated with FIGO stage (P=0.001), histological grade (P=0.032), ascites (P=0.019), lymph node metastasis (P=0.003), and tumor size (P=0.041). Among 116 patients with ovarian cancer examined, the 5-year overall survival (OS) rates were 62.5% and 22.01% in patients with high and low miR-193b expression, respectively (P=0.003). Multivariate analysis showed that tissue miR-193b is an independent prognostic factor in patients with ovarian cancer (HR=4.219; P=0.015). CONCLUSIONS Reduction of miR-193b was found in ovarian cancer and its lower expression was associated with poorer prognosis. Tissue miR-193b showed potential as novel biomarker for ovarian cancer.
authors.affiliation: Department of Gynecology and Obstetrics, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China (mainland).
authors.forename: Haiyan
authors.initials: H
authors.lastname: Li
authors.affiliation: Department of Gynecology and Obstetrics, Third hospital in Shijiazhuang, Shijiazhuang, Hebei, China (mainland).
authors.forename: Yuping
authors.initials: Y
authors.lastname: Xu
authors.affiliation: Department of Gynecology and Obstetrics, Third hospital in Shijiazhuang, Shijiazhuang, China (mainland).
authors.forename: Weifeng
authors.initials: W
authors.lastname: Qiu
authors.affiliation: Department of Gynecology and Obstetrics, Third hospital in Shijiazhuang, Shijiazhuang, Hebei, China (mainland).
authors.forename: Danni
authors.initials: D
authors.lastname: Zhao
authors.affiliation: Department of Gynecology and Obstetrics, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China (mainland).
authors.forename: Yuanzhen
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D045744:Cell Line, Tumor; D015536:Down-Regulation; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D035683:MicroRNAs / Q000378:metabolism*; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology; D012307:Risk Factors; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; C546818:MIRN193 microRNA, human; D035683:MicroRNAs